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ABSTRACT 
 
Soybeans are unique among the legumes because they are a concentrated source of isoflavones. A 
number of components of soy have been studied to investigate their potential effect on CVD. Soy 
proteins have been shown to lower LDL-cholesterol and to have neutral or slightly positive effect 
on HDL-cholesterol. However, to what extend actually is the role of the isoflavone in this action 
remained contradictive. This review describes the characteristics and the nature of the soy 
isoflavones as well as covering the results from several studies to determine the effect of soy 
isoflavones on the serum lipid and vascular functions. 
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INTRODUCTION 
 
 Soybeans are exceptional foods because of 
their rich nutrient content. These legumes contain 
complex carbohydrates, vegetable proteins, dietary 
fibre, oligosaccharides, phytochemicals, vitamins, 
and minerals (Anderson et al., 1999). What is 
known that all foods including soybean are 
complex collections of chemicals that can be 
beneficial or unfavourable for many people in 
many situations. 
 Soy by itself is not a magic food, but it is 
rather an example of different kinds of food that 
together in a complete diet can have a positive 
effect on health. As consumers have pursued 
healthier lifestyles in recent years, consumption of 
soy foods has risen steadily, encouraged by 
scientific studies showing from this products. 
Soybeans are inexpensive sources of plant protein 
with potential to be used worldwide as substitutes 
for animal-protein sources.  
 Soybeans are also unique among the 
legumes because they are concentrated source of 
isoflavones. These plant compound are structurally 
very similar to human hormone estrogen, hence 
the name used for them is phytoestrogens (Lampe, 
2003). There is a keen interest in soy isoflavones 
because they are biologically active in the human 
body and may have the potential to reduce the 
risks of certain diseases.  
 Research suggests that soy isoflavones 
maybe beneficial in menopausal health (Knight et 
al., 1996), bone health (Anderson & Carner, 
1997), cardiovascular health (Anthony et al., 
1998), cognitive health and possibly immunity. 
 Cardiovascular disease (CVD) is disease 
of heart circulation system (heart, arteries, 
capillaries, and veins). Heart disease belongs to 
this CVD, and the risk is influenced by many 
factors that include blood cholesterol, blood 
pressure, arterial stiffness, development of 
atherosclerotic plaque, etc. Soy isoflavones may 
reduce one or more of these heart disease risk 
factors.  
 Lowering elevated serum cholesterol level 
is widely acknowledged as an important in 
significantly reducing the risk of CVD. Several 
evidence have established that the consumption of 
soy protein where isoflavones are part of it lowers 
serum cholesterol. In 1999 the U.S. Food and Drug 
Administration authorized a health claim for soy 
protein and the reduced risks of heart disease 
(FDA, 1999). 
 While the hypocholesterolemic effect of 
soy protein has been well established, the role of 
isoflavones in the hypocholesterolemic effect of 
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soy is inconsistent. A meta-analysis performed 
with data compiled from 10 clinical trials found 
soy isoflavones were not associated with 
significant changes in Low Density Lipoprotein 
(LDL) cholesterol or High Density Lipoprotein 
(HDL) cholesterol (Weggemans & Trautwein, 
2003). 
 Although the data do not support the use 
of soy isoflavones by itself for serum cholesterol 
reduction, additional research suggests isoflavones 
may impact other aspects of CVD that equally 
important. Soy isoflavones have been shown in 
isolated human plasma studies to reduce LDL 
oxidation and improve platelet and clotting 
mechanisms. The data is still preliminary around, 
but the area of most promise is the effect of 
isoflavones on vascular function. Soy isoflavones 
improve compliance or elasticity of large and 
medium-sized arteries as well as improve 
endothelial-dependent dilation of peripheral blood 
vessels (Squardito et al., 2002; Steinberg et al., 
2003). 
 Therefore, this review is aimed to discuss 
the effect of soy isoflavones on the serum lipid 
profile and vascular function and to see whether 
they are more effective when used together with or 
without soy protein. 
 
CHARACTERISTICS OF SOY 
ISOFLAVONES 
  
 Isoflavones are a subclass of the more 
ever-present flavonoids. The basic structural 
feature of flavonoid compound is the flavone 
nucleus which is composed of 2 benzene rings (A 
and B) linked through a heterocyclic pyrane C ring 
(Figure 1). The position of the benzenoid B ring is 
the basis for dividing flavonoid class into 
flavonoids (2-position) and isoflavonoids (3-
position). In soybeans, isoflavones are present as 
glycosides (bound to a sugar molecule). 
Fermentation or digestion of soybeans or soy 
product results in release of the sugar molecule 
from the isoflavone glycoside, leaving an 
isoflavone aglycone. 
Soy isoflavone glycosides are called genistin, 
daidzin, and glycitin, while the aglycones are 
called genistein, daidzein, and glycitein, 
subsequently. These aglycones are the compunds 
that are commonly reffered to as isoflavone 
compounds present in soy products. Structure of 
these three isoflavones can be seen in Figure 1.  
 Isoflavones are polyphenolic compound 
that are capable of exerting estrogen-like effects. 
For this reason, they are classified as 
phytoestrogens, i.e. compounds with estrogenic 
activity derived from plants (Lampe, 2003). 
Soybeans are the richest source of soy isoflavones 
in human diets. In soybeans, isoflavones exist in 
the entire plant including the seeds, leaves, stems, 
seedling and roots. In seeds which are mostly 
consumed, isoflavones have a high concentration 
around hypocotyls (Kudou et al., 1991). The 
biological effect of soy isoflavones is strongly 
affected by their metabolism, which is dependent 
on the activity of bacteria that colonize human 
intestine (Rowland et al., 2003). Although 
glycosides of isoflavones are readily hydrolyzed 
by intestinal bacteria enzymes, Setchell (1998) 
stated that little is known about the biological 
activity of individual isoflavones. It seems that 
glycoside isoflavones are hydrolyzed by intestinal 
bacteria to aglycones prior to being absorbed. 
However, not everyone has the same intestinal 
microflora ability to hydrolyze the glycosides. 
Therefore, it is important to analyse the individual 
forms of isoflavones instead of total isoflavones in 
foods, because foods vary widely in aglycone 
contents. 
 
 
Figure 1. Structure of the primary isoflavones in 
soybeans (Messina, 1999). 
 
 Soy isoflavones are known to have weak 
estrogenic activity. Estrogens are signalling 
molecules that exert their effects by binding to 
estrogen receptors within cells. The estrogen-
receptor complex interacts with DNA to change 
the expression of estrogen responsive genes. 
Estrogen receptors are present in numerous tissues 
other than those associated with reproductive 
system including bone, liver, heart and brain. Soy 
isoflavones can bind to estrogen receptors, taking 
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off the effects of estrogen in some tissues and 
blocking the effects of estrogens in others. 
 Soy isoflavones and their metabolites also 
have biological activities that are not related to 
their interactions with estrogen receptor (Barnes et 
al., 2000). By inhibiting the synthesis and activity 
of certain enzymes involved in estrogen 
metabolism, soy isoflavones may alter the 
biological activity of endogenous estrogens. In 
addition, soy isoflavones have been found to 
inhibit tyrosine kinases, enzymes that play critical 
roles in the signalling pathways that stimulate cell 
proliferation. One of the importan roles of 
estrogen is that it influences the CVD. The role of 
estrogen deficiency in CVD was further indicated 
that the risk of CVD in women taking this 
hormone was half reduced. Therefore, the 
isoflavones act as phytoestrogens can have a 
beneficial on CVD. Many authors have suggested 
that soy isoflavones may affect plasma lipid 
concentrations through their estrogenic action or 
affect the artery walls directly (i.e., maintaining 
normal vascular function or preventing smooth 
muscle cell migration and proliferation). However, 
several studies still showed inconsistent result of 
the effect of soy isoflavones on reduced CVD 
risks. First of all, it is important to determine the 
impact, if any, of soy isoflavones on plasma lipid 
parameters. 
 
EFFECT OF ISOFLAVONES ON SERUM 
LIPID LEVELS 
 
 There are several studies conducted on 
animals as well as in humans to determine the 
effects of soy isoflavones by which they may 
modify the lipid profile. Balmir et al. (1996) 
carried out a study with casein-based diet to which 
isoflavones were added in rats. The protein 
sources were alcohol-washed soy protein isolate, 
intact protein isolate, casein, or casein to which a 
soy protein extracts rich in isoflavones was added. 
The result showed that rats fed with soy protein 
isolate and casein with isoflavones exhibited a 
decrease in plasma LDL-Cholesterol concentration 
in comparison with rats fed with alcohol washed 
soy protein isolate. This indicated that a minimal 
quantity of isoflavones may be necessary to 
obtained reduced LDL concentration. However, 
the extract obtained was composed of only 79% of 
isoflavones. The remaining 21% were unknown 
composition. Therefore, the beneficial effects of 
the extract can not be attributed with certainty to 
its isoflavone content because some other 
components present in intact soy protein isolate 
that may have an effect on plasma lipids. In 
addition, the isoflavones present in intact soybean 
protein isolate may increase the execration of 
biliary acids and promote the expression of the 
LDL receptor gene. 
 Yamakoshi et al. (2000) showed in 
rabbits, soy isoflavones may decrease 
atheroscleloris (variable combination of changes 
of the inside layer of the arterial wall) 
development by another mechanisms. Diet 
containing 1 g/100 g isoflavones aglycones had no 
effect on serum lipid profile. However, the 
atherosclerotic area of the aorta was lower in the 
high isoflavone group diet. The authors suggested 
that antioxidant action of isoflavones and their 
antioxidant metabolites soothed atherosclerotic 
development by inhibiting the oxidation of LDL. 
In another study performed in female hamster, 
alcohol washed soy protein isolate would prevent 
the total and non HDL. However, the protein 
source has no effect on total cholestrolemia, HDL, 
and non HDL, or on hepatic cholesterol 
concentration, suggesting that isoflavones or other 
non-protein components of soy may take part in 
function for cholesterol metabolism (Lucas et al., 
2001). 
 A soy protein extract rich in isoflavones 
and alcohol washed soy protein isolates was used 
in the above studies to examine the effects of 
isoflavones on the lipid profile in animals. It is still 
impossible to conclude with confidence the effects 
observed are due only to isoflavones. 
 There were several studies also conducted 
in primates because they have similarities in lipid 
metabolism with that of humans. These studies 
revealed the role of protein component in 
hypocholesterolemic effect of soy protein isolate. 
Indeed, soy protein isolate had beneficial effects 
on plasma cholesterol concentrations even when 
compared with casein to which an alcohol extract 
of soy protein was added. It then can not be 
concluded that isoflavones do or do not have any 
independent contribution to the cholesterol 
lowering effect of soy (Wagner et al., 1997; 
Greaves et al., 1999). In addition, in monkeys 
large LDL are more atherogenic than small LDL. 
In humans, however, an increase in small, dense 
LDL concentrations is associated with higher risk 
of CVD. 
 Controlled clinical studies have been 
conducted to make clear the role of isoflavones in 
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the preclusion of CVD and above all their effect 
on serum lipid profile. It has been studied mostly 
in post-menopausal women. In the early studies, a 
soy protein isolates was often used as the source of 
isoflavones. Crouse et al. (1999) tried to see the 
effect of isolated soy protein with naturally 
occurring isoflavones on lipids and lipoprotein 
whether the cholesterol lowering effect of soy is 
due to the soy protein alone or to soy isoflavones 
in soy protein. The subjects 156 people with LDL-
cholesterol ≥ 140 mg/dl serum were subjected to 
five diet intervention group: 25 g of casein, 25 g of 
isolated soy protein containing either 3, 27, 37, or 
62 mg isoflavones. The results showed that 
isolated soy protein with 62 mg of naturally 
occurring isoflavones reduces total cholesterol and 
LDL-cholesterol levels more than isolated soy 
protein with trace amounts of isoflavones. Across 
the range of 3 to 62 mg isoflavones, the isolated 
soy protein with higher levels of naturally 
occurring isoflavones resulted in even greater 
cholesterol lowering. Isolated soy protein with 
naturally occurring isoflavones had a greater 
cholesterol lowering effect in individuals with 
higher baseline cholesterol levels. 
 Studies in Asian postmenopausal women 
with normal baseline cholesterol levels showed no 
significant effect of isoflavones on total, LDL, and 
HDL cholesterol concentrations at the end of the 
study in comparison with placebo or baseline 
values (Uesugi et al., 2002). It is possible that 
usual elevated consumption of isoflavones may 
have attenuated the ultimate effect of isoflavones 
on serum lipid in these studies. However, when 40 
0r 80 mg of soy isoflavones were supplemented to 
Australian postmenopausal women in whom initial 
serum lipid was normal or slightly elevated, no 
effect was observed on serum lipid profile (Netsel 
et al., 1997). In their study, peri and 
postmenopausal women were treated with 80 mg 
isoflavones in a tablet or with a placebo pill and 
then these groups were switched to receive to 
other treatment. They found that the isoflavones 
pills had no effects on plasma lipid concentrations, 
although they did find a beneficial effect on 
systemic arterial compliance (a measure of 
elasticity of arteries). 
 On the contrary, it can be put forward that 
the impact of  isoflavones on serum lipid profile 
maybe asserted in hypercholesterolemic than in 
normocholesterolemic subjects, as in the case for 
the effect for soy protein (Anderson et al., 1995). 
They showed that hypocholesterolemic effect of 
soy protein was more asserted in subjects with 
high baseline cholesterol concentrations. In the 
study of Lichtenstein et al. (2002), the 
hypolipidemic effect of soy protein in 
hypercholesterolemic subjects was independent 
from a possible effect of isoflavones. It can be put 
forward that similar to the effect of soy protein, 
the possible impact of  isoflavones on serum lipids 
may be observed only in subjects with high 
baseline plasma cholesterol concentrations. 
 Therefore, it can be suggested that 
isoflavones might need to be given in the presence 
of soy protein in order to have their effects on 
plasma lipids. However, the finding of beneficial 
effect of the purified isoflvones pills on systemic 
arterial compliance might suggest that purified 
isoflavones do have some biologic effects.  
 
EFFECT OF SOY ISOFLAVONES ON THE 
VASCULAR FUNCTION 
 
 The other possible effect of soy 
isoflavones to reduce the risk of CVD is their 
effect on the vascular function. There were several 
studies conducted to confirm this feature. Normal 
vascular function was maintained in 
premenopausal monkeys fed soy protein with 
isoflavones compared to a group fed isoflovone-
devoid soy protein and genistein restored normal 
vascular function in the latter group (Honore et al., 
1997). They reported that in females fed with low 
isoflavone diet, arteries constricted in response to 
acetycholine (an endothelium-dependent vascular 
response), whereas arteries from female fed a high 
isoflavone diet dilated. Moreover, genistein 
administered intravenously to animals fed to the 
low isoflavone diet resulted in dilation in 
previously constricted vessels. They concluded 
that dietary isoflavones enhance dilator response 
to acetylcholine of arteries in female monkeys. 
 In placebo-controlled, randomized, cross 
over study with 21 peri- and post-menopausal 
women, treatment for 5 weeks with 80 mg/day of 
purified soy isoflavones (45 mg genistein) 
improved systemic arterial compliance, and 
indicator of vascular elasticity by 26%, 
acetylcholine-mediation dilation in forearm similar 
in placebo groups, and no changes was observed in 
arterial pressure (Nestel et al., 1997). It then can 
be suggested that soy isoflavones significantly 
improved systemic arterial compliance in 
perimenopausal and menopausal women. 
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 Another important mechanism by which 
soy isoflavones might improve CVD is the effect 
they have on platelets. Williams & Clarckson 
(1998) used 12 female non human primates. The 
results showed that a group fed soy protein isolate 
without the isoflavones had a 26% greater 
reduction in blood flow after collagen-induced 
platelet activation than did a group fed soy protein 
isolate with the isoflavones. The precise 
mechanism for this protection against reduction in 
blood flow by the isoflavones could not be 
determined in this study. The isoflavones might 
inhibit platelet activation and aggregation and 
reduce the amount of serotonin in the paltelets, all 
of which could contribute to a reduction in 
coronary vasopasm and thrombosis. 
 Anthony et al. (1997) tried to see the 
effect of isolated soy protein with or without 
isoflavones on atherosclerosis in male non human 
primates. The results showed that those in soy plus 
isoflavones with atherosclerotic plaques had 
smaller lesions, compared with other group 
(without isoflavones). They then concluded that 
beneficial effects of isolated soy protein on 
atherosclerosis appear to be mediated primarily by 
the isoflavone component and could not determine 
if the beneficial effects seen in soy without 
isoflavones were related to the protein itself or to 
the trace amounts of isoflavones remaining. 
 
CONCLUSION 
 
 A number of components of soy have been 
studied to investigate their potential effect on 
CVD. Soy proteins have been shown to lower 
LDL-Cholesterol and to have neutral or slightly 
positive effect on HDL-Cholesterol. Greater 
cholesterol lowering effects were observed as the 
level of naturally occurring isoflavones in soy 
protein increased; however, extracted isoflavones 
(without soy protein) do not appear to lower 
cholesterol levels. Therefore it might be possible 
to say that isoflavones will be much effective in 
lowering LDL as applied together with soy 
protein. 
 The results obtained on the effects of 
isoflavones in humans and animals were not 
consistent. It is likely due to great variability in the 
design experiment. If isoflavones have any 
beneficial effects in humans, it is apparently of 
small amplitude in comparison with the effect of 
soy protein itself. Consumption of soy protein 
without isoflavones does not have the same 
benefits on cholesterol lowering as soy protein 
with isoflavones. Furthermore, the determination 
of individual isoflavone plasma concentrations 
should assist greatly in determination of the true 
impact of isoflavones on human lipid metabolism. 
Even though there is presently little evidence that 
isoflavones may improve the lipid profile on their 
own, they may have other benefical effects that 
may prevent CVD. Soy protein with isoflavones 
and/or soy isoflavones may potentially inhibit 
atherosclerosis; improve systemic arterial 
compliance and reactivity in arteries; have actions 
at steps in coagulation which may inhibit vascular 
lesions. 
 While there is quite convincing evidence 
that soybean with isoflavones have beneficial 
effects on CVD risk factors and atherosclerosis, 
there remain unanswered questions. First, 
uncertainty of what amount of soy protein and 
isoflavones is necessary to have maximal benefits 
and minimal risks. Second, what is the optimal 
combination of isoflavones, i.e. whether genistein 
the active isoflavone or the mixture of genistein, 
daidzein, and glycitein is more effective? Third, to 
what extend is the possibility of the unknown 
compounds to contribute to this beneficial effect. 
Still further research is needed to account these 
features. 
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